1 ; EFFECTS PROPERTIES MUCUS WHAT CF ON ARE CALCIUM PHYSICAL PATIENTS THE OF FROM
2 ; RESPIRATORY ONE EFFECTS MUCUS TRACT DISTINGUISH SUBMUCOSAL CF HYPERSECRETION ON IN BETWEEN AND THE OF GLANDS INFECTION CAN
3 ; SALIVARY GLYCOPROTEINS HOW CF ARE DIFFERENT PATIENTS THOSE OF FROM SUBJECTS NORMAL
4 ; IS RESPIRATORY WHAT CF LIPID SECRETIONS THE OF COMPOSITION
5 ; ABNORMAL IS CF MUCUS
6 ; IS PROPERTIES ELASTICITY WHAT WATER THERAPEUTIC CF ON OR PHYSICAL VISCOSITY SECRETIONS THE PATIENTS BRONCHIAL OF AGENTS SPUTUM OTHER EFFECT FROM
7 ; MUCUS GLYCOPROTEINS TO CF AS DIFFERENTLY IN DEGRADED COMPARED ARE THOSE PATIENTS FROM SUBJECTS NORMAL
8 ; RESPIRATORY DIFFERENCES BEEN WHAT CF HAVE EPITHELIA BETWEEN AND DESCRIBED HISTOCHEMICAL NORMAL
9 ; IS LIVER VITAMIN WHAT METABOLISM CF ASSOCIATION CIRRHOSIS IN BETWEEN DISEASE THE AND
10 ; IS VITAMIN ROLE WITH WHAT CF IN PATIENTS THE OF THERAPY
11 ; IS WHAT SYNDROME DIFFERENCE PLUG BETWEEN MECONIUM THE AND ILEUS
12 ; SMALL BEEN WHAT TRANSPORT HAVE CF ABNORMALITIES BOWEL IN AMINO PATIENTS THE OF ACID DESCRIBED
13 ; PANCREATITIS WHAT CF IN OR BIOCHEMICAL ARE CLINICAL PATIENTS THE OF FEATURES
14 ; TESTS FOR PERFORMED NON-INVASIVE EVALUATION WHAT WITH CF IN EXOCRINE PATIENTS FUNCTION THE BE OF PANCREATIC CAN
15 ; COMPLICATIONS WHAT CF OR ARE HEPATIC MANIFESTATIONS THE OF
16 ; NEONATAL LIVER COMPLICATIONS WHAT CF GASTROINTESTINAL AFTER ARE DISEASE AND THE MECONIUM OF PERIOD ILEUS EXCLUDE
17 ; SUPPLEMENTS IS FOR EFFECTIVE TREATMENT WHAT CF IN PATIENTS USE THE ENZYME OF PANCREATIC MOST REGIMEN
18 ; IS BENEFIT WITH BILE TO CF THERAPEUTIC SALTS SUPPLEMENTATION PATIENTS DIETARY OF
19 ; REPORTED COMPLICATIONS BEEN WHAT CF HAVE IN PATIENTS ENZYME OF PANCREATIC THERAPY
20 ; IS TREATMENT WITH WHAT CF ESSENTIAL PATIENTS THE FATTY OF ACID EFFECT SUPPLEMENTS
21 ; INSUFFICIENCY METABOLIZE TO ABILITY CF IN DOES ABSORB OR THEIR PATIENTS PANCREATIC IRON AFFECT
22 ; IS POPULATIONS WHAT CF IN THE OF FREQUENCY NON-CAUCASIAN
23 ; WITH DISEASES WHAT BEEN HAVE ASSOCIATION CF IN OR CONDITIONS CONGENITAL HEREDITARY FOUND
24 ; MANIFESTED WHOM IS CHARACTERISTICS WHAT CF IN INCOMPLETELY ARE PATIENTS THE OF
25 ; INVOLVES IS THAT ONE GENETIC FOR BASIS WHAT CF THAN GENE THE EVIDENCE THERE MORE
26 ; IS WHAT CF HETEROZYGOTE IN THE ADVANTAGE
27 ; IS WHOM CONCORDANCE WHAT CF HAVE SIBLING IN OR BIOCHEMICAL CLINICAL MANIFESTATIONS PAIRS BOTH THE OF
28 ; IS MALE WHAT CF IN THE OF INCIDENCE FERTILITY
29 ; IS MALE SYSTEM WHAT CF IN OR FEMALE PATHOLOGY THE OF REPRODUCTIVE
30 ; COUNSELING FAMILIES GENETIC WITH WHAT CF CHILDREN ARE THE RESULTS OF
31 ; PSYCHOLOGICAL FAMILIES EFFECTS WHAT CF SOCIAL ON OR ARE THEIR PATIENTS AND MAJOR THE OF
32 ; INFLUENCE WITH WHAT CF COMPLIANCE IN PRESCRIBED PATIENTS THERAPY FACTORS
33 ; ERRONEOUS TESTS TO WHAT LEAD SWEAT OR CONDITIONS FACTORS
34 ; GIBSON-COOKE CHLORIDE FOR SWEAT ARE THEIR THE TESTING AVAILABLE PILOCARPINE THAN AND ANALYSIS CLASSICAL IONTOPHORESIS TITRIMETRIC ADVANTAGES OTHER RELATIVE WITH WHAT ALTERNATIVE TEST QUANTITATIVE TECHNIQUES OF DISADVANTAGES
35 ; TESTS PATIENT TO ANY BEEN CF HAVE SWEAT HAS CONSISTENTLY FOUND NORMAL
36 ; IS POTASSIUM WHAT CF CONCENTRATION IN SWEAT PATIENTS THE OF FROM
37 ; NEWBORN ERRONEOUS TESTS INFANTS FOR TO WHAT CF TECHNIQUES ARE SCREENING CONTRIBUTE AND THESE RESULTS OF AVAILABLE FACTORS
38 ; BE CF PRENATALLY CAN DIAGNOSED
39 ; FOR HOW CF IDENTIFIED HETEROZYGOTES MAY BE
40 ; NEONATAL FOR TEST WHAT CF THAN TECHNIQUES SWEAT THE USEFUL MAY BE BEYOND PERIOD OTHER DIAGNOSIS OF
41 ; IS VITAMIN METABOLISM CF IN PATIENTS NORMAL
42 ; SECRETION WHAT METABOLISM INSULIN CF ABNORMALITIES IN OR PATIENTS OF OCCUR
43 ; IS CHLORIDE SODIUM CF IN SALT ABNORMAL AND/OR TRANSPORT/PERMEABILITY
44 ; DIFFERENCES WHAT CF ENZYMATIC OR ARE NON-CF PATIENTS BETWEEN FIBROBLASTS AND STRUCTURAL FROM THERE
45 ; PROSTAGLANDIN BEEN WHAT METABOLISM HAVE CF ABNORMALITIES IN PATIENTS OF DESCRIBED
46 ; ENZYMES ACTIVITY PROPERTIES GALACTOSYLTRANSFERASE WHAT CF ARE PATIENTS AND THE OF FROM
47 ; HORMONES DIFFERENCES BEEN WHAT CF HAVE METABOLISM IN OR PATIENTS AND BETWEEN THE FUNCTION DESCRIBED OF SUBJECTS NORMAL
48 ; RATE AT DO GROW CF PATIENTS FIBROBLASTS FROM NORMAL
49 ; IS METABOLISM CF IN OR POLYAMINE PATIENTS METHYLATION RNA NORMAL
50 ; BEEN WHAT METABOLISM HAVE CF IN OR NUCLEOTIDES PATIENTS THE DEFECTS CYCLIC OF DESCRIBED SYNTHESIS
51 ; CF ARE BIOLOGICALLY THOUGHT ACTIVE '' SOME BEEN UNIDENTIFIED OR PLAY ROLE `` CYSTIC CIRCULATING SECRETED DESCRIBED TO WHAT HAVE FIBROSIS IN PATIENTS PATHOGENETIC MOLECULES FACTORS
52 ; IS PROLACTIN WHAT CF IN PATIENTS KNOWN ABOUT
53 ; BACTERIAL IGA AGAINST CF COLONIZATION PROTECT DOES OR SECRETORY PATIENTS INFECTION
54 ; IS HYPERSENSITIVITY TO WHAT CF IN OR RELATIONSHIP PATIENTS DISEASE THE ALLERGY OF LUNG
55 ; ENDOGENOUS INTERACTIONS BACTERIAL ORIGIN WHAT CF ANTIPROTEASES IN OR ARE PATIENTS BETWEEN PROTEASES THE AND OF LUNGS
56 ; IS BACTERIAL AGAINST WHAT NUTRITION CF IN DEFENSES RELATIONSHIP PATIENTS BETWEEN AND THE HOST INFECTION PULMONARY
57 ; IS ROLE TO WHAT CF PSEUDOMONAS CIRCULATING ANTIBODIES IN PATHOPHYSIOLOGIC PATIENTS THE AERUGINOSA OF
58 ; IS TO WHAT CF IN IMMUNOLOGIC RESPONSE PATIENTS THE INFECTION PULMONARY
59 ; BEEN WHAT CF HAVE ABNORMALITIES IN IMMUNOLOGIC PATIENTS FOUND
60 ; EFFECTS WHAT CF ON ARE THE OF CIRCULATION PULMONARY
61 ; IS RESPIRATORY TRACT MUCOCILIARY TRANSPORT CF IN DEFECT PATIENTS THE OF THERE CLEARANCE
62 ; WHAT CF IN ARE CLINICAL PATIENTS DISEASE THE OF FEATURES LUNG
63 ; CHARACTERISTICS WHAT CF IN BIOCHEMICAL OR ARE INFLAMMATION PATIENTS THE AIRWAY OF MICROSCOPIC
64 ; CHANGE WITH HOW PERIODS CF GREATER THAN DOES IN DAY TIME PATIENTS FUNCTION LUNG
65 ; WHAT CF ABNORMALITIES IN ARE PATIENTS FUNCTION THE OF PULMONARY
66 ; PATHOLOGIC WHAT CF IN ARE PATIENTS DISEASE THE OF FEATURES LUNG
67 ; IS RESPIRATORY PROGNOSIS FOR WHO WHAT EPISODE HAVE FAILURE PATIENTS THE OF HAD AN
68 ; EFFECTS WHAT CF IN ARE PATIENTS THE OF BRONCHODILATORS
69 ; IS TREAT BEST PNEUMOTHORAX TO WHAT CF WAY IN PATIENTS THE
70 ; IS PROGNOSIS FOR TREATMENT WHAT CF IN PATIENTS AND THE OF HEMOPTYSIS
71 ; IS PROGNOSIS INFANTS FOR WITH WHAT FIBROSIS CYSTIC AND THE WHEEZING
72 ; IS BEST FOR TREATMENT NASAL WHAT CF IN PATIENTS THE POLYPS
73 ; IS LAVAGE EFFECTIVE HOW CF IN PATIENTS BRONCHIAL
74 ; RESPIRATORY WITH WHAT CF IN ARE FAILURE MECHANICAL PATIENTS VENTILATION THE RESULTS OF
75 ; IS BEST FOR TREATMENT WHAT CF PULMONALE IN COR HYPERTENSION PATIENTS THE PULMONARY AND/OR
76 ; EXERCISE EFFECTS WHAT CF ON TRAINING PROGRAMS IN ARE PATIENTS FUNCTION THE OF LUNG
77 ; MUCUS EFFECTIVE WHAT CF PROMOTING IN TECHNIQUES ARE PATIENTS THE OF FROM LUNGS CLEARANCE
78 ; FOR CF ARE THE PROBLEMS IE OR THERE PHARMACODYNAMICS TREATMENT SPECIAL DIFFERENT OTHER ANTIBIOTICS PECULIAR CONSIDERATIONS WITH WHAT TO IN PATIENTS OF
79 ; IS ROLE ANTIBIOTICS ADMINISTERED TREATMENT WHAT CF IN PATIENTS THE OF ORALLY
80 ; IS THAT COMBINATION EFFECTIVE WITH WHAT PENICILLINS THAN SEMISYNTHETIC AMINOGLYCOSIDES EITHER AND THE EVIDENCE THERAPY ALONE MORE
81 ; MUCOLYTIC EFFECTIVE INHALATIONS HOW TREATMENT CF IN ARE PATIENTS THE OF AGENTS
82 ; IS ROLE TREATMENT WHAT CF IN AEROSOLS PATIENTS DISEASE THE OF LUNG
83 ; IS ROLE BACTERIAL WHAT CF IN OR MACROPHAGES LEUKOCYTES DISEASE PATIENTS THE PHAGOCYTOSIS OF POLYMORPHONUCLEAR ALVEOLAR BY LUNG
84 ; IS WHAT CF HAEMOPHILUS PSEUDOMONAS IN RELATIONSHIP INFLUENZAE PATIENTS BETWEEN AND THE AERUGINOSA
85 ; DO WHAT CF EVER DEVELOP THAN IN IF ORGANS PATIENTS THE SO INFECTION OTHER LUNG
86 ; IS STAPHYLOCOCCUS ROLE PATHOGENESIS WHAT CF THAN PSEUDOMONAS HAEMOPHILUS AUREUS OR BACTERIA INFLUENZAE IN PATIENTS DISEASE THE AERUGINOSA OF OTHER LUNG
87 ; IS ROLE PATHOGENESIS WHAT CF IN PATIENTS DISEASE FUNGI THE OF LUNG
88 ; VIRAL IS ROLE WHAT CF IN PATIENTS DISEASE THE OF INFECTION LUNG
89 ; IS DO INDIVIDUALS TO EPIDEMIOLOGY WHAT CF PSEUDOMONAS SPREAD IN OR SPECIFICALLY PATIENTS THE FAMILY AERUGINOSA OF OTHER
90 ; RESPONSIBLE FOR WHAT CF PSEUDOMONAS IN MUCOID ARE PATIENTS THE APPEARANCE STRAINS OF AERUGINOSA FACTORS
91 ; INSUFFICIENCY WHAT CF THAN OR EXOCRINE ARE MANIFESTATIONS UNUSUAL DISEASE THE OF PANCREATIC OTHER LUNG
92 ; IS PROGNOSIS FOR WITH WHAT CF PATIENTS THE SURVIVAL OF
94 ; TO WHAT CF RELEVANT ANIMAL ARE WHICH MODELS AVAILABLE
95 ; BEEN WHAT CF SKELETAL HAVE ABNORMALITIES IN OR PATIENTS FUNCTION STRUCTURE OF MUSCLE FOUND
96 ; INCREASED IS CARIES PROBLEMS EG CF PERIODONTAL IN DENTAL OR PATIENTS DISEASE OF THERE INCIDENCE AN
97 ; IS TRANSPORT CF IN RED OXYGEN PATIENTS BLOOD CELLS ABNORMAL BY
98 ; EFFECTS SYSTEM WHAT CF CENTRAL ON BRAIN NERVOUS ARE AND FUNCTION THE OF DEVELOPMENT AND/OR
99 ; CF ABNORMALITIES IN ARE TASTE PATIENTS OF THERE
100 ; IS FOR TREATMENT WHAT HYPERTROPHIC CF IN PATIENTS AND THE OF OSTEOARTHROPATHY INCIDENCE